Benzinga | Apr 22, 2021 07:32AM EDT

Akari Therapeutics Announces Poster Presentation Of Phase II Bullous Pemphigoid Disease And Phase III Trial Design At American Academy Of Dermatology Association Virtual Meeting Experience Apr. 23

Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and leukotriene systems are implicated, announced today that it will present a poster at the American Academy of Dermatology Association (AAD) Virtual Meeting Experience (VMX) taking place April 23-25, 2021.



The poster will be made available on AAD's VMX platform beginning April 23, 2021, and the Akari corporate website at http://investor.akaritx.com/news-and-events/presentations following the meeting.

Poster Details

Title: "Disease Remission During a Short-term Treatment Phase II Study of Nomacopan in Mild-to-moderate Bullous Pemphigoid"

Category: Immunodermatology & Blistering Disorders

Presentation date: April 23, 2021

Presentation Time: Beginning 9:00 a.m. CT

The poster describes results from the completed Phase II study (NCT04035733) of nomacopan for treatment of bullous pemphigoid (BP), with a specific focus on the disease control recorded at each clinical visit during the short-term (6-week) treatment period. Disease control is an important variable, as it will be used to decide when to taper the adjunct oral corticosteroid dose in the upcoming 24-week nomacopan treatment Phase III BP randomized controlled trial whose design is also presented in the poster.

The Phase III trial in moderate to severe BP patients was refined following successful end of Phase II meetings with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The trial is anticipated to open for recruitment in the U.S. and Europe mid-2021. Earlier this month, Akari announced that the FDA investigational new drug application (IND) is now open in the U.S. for the BP Phase III trial.